← Back

Wire · operational-macro

US FDA approves Sanofi's genetic disorder drug

Published

18 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at reuters.com →

◆ Verified

Fusion42 · 19 November 2026 · Fusion42 review

The US FDA approved Sanofi's oral drug Venglustat, branded as Infilbray, as the first treatment for type 3 Gaucher disease, a rare genetic condition affecting the brain and nervous system. The approval is based on clinical trial results showing improvement in muscle control, coordination, and thinking ability for patients, with regulatory reviews ongoing in the EU and Japan.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You have a new market opening for neurological rare disorder therapies as the FDA clears a drug that reaches the brain, unlike older enzyme replacements. This sets a precedent to prioritise treatments that can cross the blood-brain barrier in your R&D pipeline.

◆ Coverage

2 sources · 18 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalgenetic-disorderrare-diseasesanofibiotechclinical-trial